Announcement of Interim Results
EKF Diagnostics Holdings plc (AIM: EKF), the point-of-care diagnostics business, announces its unaudited interim results for the six month period ended 30 June 2011, a period of transition, investment and progression.
Given the acquisitions completed in the last 12 months the year-on-year comparisons given in the highlights below show 2011 actual figures versus pro-forma figures for 2010 based on a like-for-like comparison for the first six months of the year.
Financial Highlights
• Revenues up 23% to £7.38m (H1’10: £6.01m)
• Gross margins improved to 64% from 58% – but still impacted by strategy of placing Quo-Test at cost
• Operating loss of £1.49m (H1’10: loss of £0.66m) – reflecting investment in infrastructure and increased overhead
• Adjusted EBITDA of £210k (H1’10: loss of £51k)
• Cash at 30 June 2011 of £5.52m
Operational Highlights
• Acquisition of Stanbio for an overall consideration of c. £16m
• Agreement signed with Alere for distribution of CLIA waived Hemo_Control device and cuvettes
• SFDA approval for Quo-Test in China
• Cumulative placement of 1,000 Quo-Test instruments by September
• Development of Quo-Lab for Medica launch in November with first shipments expected in Q1’12
• Successful development of Argutus kidney markers onto POC platform
• Richard Evans appointed as full-time Finance Director
Post-period end
• Richard Evans appointed as Finance Director as of 28 September 2011 (see separate RNS)
• 1,000th Quo-Test instrument expected to be placed by end of September 2011
• Quo-Lab to be launched at Medica (Nov 2011); first shipments expected Q1 2012
Commenting on Outlook, David Evans, Executive Chairman of EKF, said:
“Trading continues to be in line with management expectations. We remain confident with regard to our future growth which will continue both organically and via acquisition.”
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.